14 research outputs found
Quelques aspects de la réaction du phénylisothiocyanate avec les amino-acides et peptides
No full textDoctorat en Sciencesinfo:eu-repo/semantics/nonPublishe
Activité de la déhydrogénase isocitrique dans le liquide céphalo-rachidien normal et pathologique
No full textEnzymes in cancer.III. Triosephosphate isomerase activity of human blood serum in normal individuals and in individuals with various pathological conditions
Full text linkPhase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck
No full textMicrobiome metabolic potency towards plant bioactives and consequences for health effects
No full textIn vitro and in situ activity-based labeling of fibroblast activation protein with UAMC1110-derived probes
No full textCombination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
Full text linkNext generation fibroblast activation protein (FAP) targeting PET tracers : the tetrazine ligation allows an easy and convenient way to \ub9\u2078F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines
No full textAbstract: Small-molecular fibroblast activation protein inhibitor (FAPI)-based tracer have been shown to be promising Positron Emission Tomography (PET) 68Ga-labeled radiopharmaceuticals to image a variety of tumors including pancreatic, breast, and colorectal cancers, among others. In this study, we developed a novel 18F-labeled FAPI derivative. [18F]6 was labeled using a synthon approach based on the tetrazine ligation. It showed subnanomolar affinity for the FAP protein and a good selectivity profile against known off-target proteases. Small animal PET studies revealed high tumor uptake and good target-to-background ratios. [18F]6 was excreted via the liver. Overall, [18F]6 showed promising characteristics to be used as a PET tracer and could serve as a lead for further development of halogen-based theranostic FAPI radiopharmaceuticals
Modification in the activity of some enzymes of the cerebrospinal fluid in patients with intracranial tumors
No full text
